Document is current

Article History

Accepted: 19 January 2022

First Online: 5 February 2022

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki 2013 [] and was approved by the Regional Ethics Board, Lund (file nr 2016/1105, for the Quantitative part of the study, and file number 2017/2024 for the Qualitative part of the study). Prior to patient inclusion, both for the quantitative and the qualitative part of the study, oral and written information about the study was given to all patients prior to retrieving a written consent. No economic compensation was provided for study participation in the quantitative part whereas participants in the qualitative part of the study received a grocery store gift voucher valid for SEK 100 (≈ 10 USD).

: Not applicable.

: Håkansson holds a position at Lund University sponsored by the Swedish state-owned gambling operator AB Svenska Spel. He disposes research grants from the research councils of AB Svenska Spel, the state-owned alcohol monopoly Systembolaget, the Swedish Enforcement Agency, and the Swedish Sports Federation. He is currently involved in a clinical research study which receives non-financial support from the commercial body Kontigo Care in digital follow-up tools in the treatment of addictive disorders. He is the national principal investigator of a prior pharmaco-epidemiological survey study conducted by the US research institute Research Triangle Institute and which was sponsored by a pharmaceutical company (Shire), which supported the study but did not pay any personal fees to Håkansson as an individual researcher. The present competing interests are not involved in the present project. Authors Troberg, Dahlman, Hansson and Lundqvist declare that they have no conflicts of interest related to this study.